Get the Stockscreener App
3.4748
2.06%
0.0748
Fortress Biotech Inc stock is traded at $3.4748, with a volume of 210.95K.
It is up +2.06% in the last 24 hours and down -7.22% over the past month.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
See More
Previous Close:
$3.40
Open:
$3.4
24h Volume:
210.95K
Relative Volume:
0.32
Market Cap:
$107.86M
Revenue:
$80.97M
Net Income/Loss:
$-78.31M
P/E Ratio:
-0.3135
EPS:
-11.0849
Net Cash Flow:
$-129.56M
1W Performance:
-0.29%
1M Performance:
-7.22%
6M Performance:
+76.14%
1Y Performance:
+92.78%
1-Day Range:
$3.3275
$3.50
1-Week Range:
$3.27
$3.60
52-Week Range:
$1.325
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
Name
Fortress Biotech Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
3.475 | 105.53M | 80.97M | -78.31M | -129.56M | -11.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.10 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.45 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.92 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.09 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.12 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-24 | Resumed | ROTH MKM | Buy |
| Aug-04-22 | Initiated | Ladenburg Thalmann | Buy |
| Oct-02-20 | Initiated | The Benchmark Company | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Feb-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-22-17 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-16 | Initiated | ROTH Capital | Buy |
View All
Fortress Biotech Inc Stock (FBIO) Latest News
Aug Technicals: Can Fortress Biotech Inc deliver alpha2025 Growth vs Value & Weekly Momentum Picks - baoquankhu1.vn
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened - Defense World
ETF Watch: How liquid is OS Therapies Incorporated stockIPO Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
How (FBIOP) Movements Inform Risk Allocation Models - Stock Traders Daily
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability - Yahoo Finance
Zacks Research Upgrades Fortress Biotech (NASDAQ:FBIO) to Strong-Buy - MarketBeat
Analysts Issue Forecasts for FBIO FY2025 Earnings - Defense World
Fortress Bio gains on FDA approval of copper replacement therapy - MSN
Research Analysts Set Expectations for FBIO FY2025 Earnings - MarketBeat
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease - Stocktwits
Risk Hedge: What are the risks of holding Fortress Biotech IncGap Down & Low Risk Entry Point Guides - baoquankhu1.vn
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO, the First and Only Approved Treatment for Menkes Disease in the United States - marketscreener.com
US FDA approves Fortress Bio and Zydus’ treatment for a rare pediatric disease - whtc.com
Investors Purchase Large Volume of Fortress Biotech Call Options (NASDAQ:FBIO) - MarketBeat
Fortress Biotech (FBIO) Surges After FDA Approval for Zycubo - GuruFocus
US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease - Reuters
Fortress Biotech Gains FDA Approval for Menkes Treatment - TipRanks
Fortress Bio wins FDA nod for Menkes disease drug (FBIO:NASDAQ) - Seeking Alpha
Fortress Biotech and Cyprium Therapeutics Announce U.S. Fda Approval of Zycubo - marketscreener.com
FDA Approves Fortress Biotech's ZYCUBO for Pediatric Menkes Dise - GuruFocus
Fortress Biotech, Cyprium Say FDA Approved Zycubo for Pediatric Patients of Menkes Disease; Shares Rise Pre-Bell - marketscreener.com
Fortress Biotech and Cyprium Therapeutics Announce FDA Approval of ZYCUBO for Menkes Disease and Transfer of Rare Pediatric Disease Priority Review Voucher from Sentynl Therapeutics - Quiver Quantitative
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA - GlobeNewswire
Fortress Biotech's Subsidiary Nears Key FDA Decision, Shares Rise 3% - Intellectia AI
Trading Systems Reacting to (FBIOP) Volatility - Stock Traders Daily
Fortress Biotech (NASDAQ:FBIOP) Shares Up 2.4% – Should You Buy? - Defense World
Will Fortress Biotech Inc.(CNB0) stock rise with strong economyMarket Sentiment Summary & Risk Managed Investment Signals - Улправда
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Aug Rallies: Can Fortress Biotech Inc. stock hit record highs againBond Market & AI Optimized Trade Strategies - Улправда
Will Fortress Biotech Inc. stock benefit from AI adoptionOptions Play & Short-Term Trading Alerts - ulpravda.ru
Can Fortress Biotech Inc. stock hit record highs againMarket Movement Recap & Daily Profit Maximizing Tips - Улправда
How Fortress Biotech Inc. stock compares to industry benchmarksJobs Report & Real-Time Buy Signal Alerts - ulpravda.ru
Will Fortress Biotech Inc. stock outperform international peersJuly 2025 Review & Expert Verified Stock Movement Alerts - Улправда
Is Fortress Biotech Inc.(CNB0) stock testing key supportWeekly Investment Report & Stepwise Entry/Exit Trade Alerts - Улправда
Fortress Biotech amends credit agreement with Oaktree - MSN
Fortress Biotech (NASDAQ: FBIO) reports 13.4% Avenue (ATXI) stake with voting control - Stock Titan
Avenue Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Fortress Biotech, Inc. - 富途牛牛
Head-To-Head Comparison: Fortress Biotech (NASDAQ:FBIO) & WAVE Life Sciences (NASDAQ:WVE) - Defense World
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates - ADVFN
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults - ADVFN
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
How Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Affects Rotational Strategy Timing - Stock Traders Daily
Signal Recap: Will Fortress Biotech Inc stock benefit from AI adoptionMarket Sentiment Report & Consistent Profit Trading Strategies - moha.gov.vn
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
What analysts say about Fortress Biotech Inc stockEx-Dividend Date Alerts & High Yield Portfolio Growth - earlytimes.in
(FBIOP) Risk Channels and Responsive Allocation - Stock Traders Daily
Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 28% Price Jump - 富途牛牛
Is Fortress Biotech Inc.(CNB0) stock resilient in recession scenarios2025 Market WrapUp & AI Powered Market Trend Analysis - Улправда
Fortress Biotech (NASDAQ: FBIO) registers 600,000 shares for Oaktree resale - Stock Titan
What momentum indicators show for Fortress Biotech Inc. stockJuly 2025 Big Picture & Weekly Setup with High ROI Potential - Улправда
Fortress Biotech Inc Stock (FBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.26%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):